# Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

> **NCT05053503** · NA · COMPLETED · sponsor: **Spark Biomedical, Inc.** · enrollment: 108 (actual)

## Conditions studied

- Opioid-use Disorder
- Opioid Withdrawal

## Interventions

- **DEVICE:** Sparrow Ascent Therapy System
- **DRUG:** Lofexidine
- **DRUG:** Extended-release injectable naltrexone

## Key facts

- **NCT ID:** NCT05053503
- **Lead sponsor:** Spark Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-27
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-04-04
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053503, "Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05053503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*